Table 2 Treatment-related adverse events
Events | Safety set (n = 60) |
|---|---|
Any TRAE | 60 (100.0%) |
Grade ≥ 3 TRAEs | 26 (43.3%) |
Serious TRAEs | 1 (1.7%) |
TRAEs leading to dose interruption, any drug | 23 (38.3%) |
TRAEs leading to dose interruption, anlotinib | 23 (38.3%) |
TRAEs leading to dose interruption, icotinib | 2 (3.3%) |
TRAEs leading to dose reduction, any drug | 15 (25.0%) |
TRAEs leading to dose reduction, anlotinib | 15 (25.0%) |
TRAEs leading to dose reduction, icotinib | 0 |
Discontinued combined therapy due to TRAEs | 5 (8.3%) |